☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Share this
PS Admin
Jun 20, 2024
Clinical Trials
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Click here
to read the full press release
Comments
Fill this Details
×
Name
Email
Company Name
Thank you for download PDF
Submit
Related News/Articles
Tubulis Reports the US FDA’s Fast Track Designation of TUB-040 to Treat Ovarian Cancer
June 28, 2024
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-aa
June 20, 2024
Reuters Pharma 2025: Pre-Conference Talks Featuring Vikram Mohan
April 2, 2025
Evaluating SDoH in Lupus Nephritis: Roger Levy from GSK in a Stimulating Conversation with PharmaShots
April 2, 2025
Intelligent Automation and Beyond: Dale Curtis Jr from Astrix in an Enlightening Conversation with PharmaShots
January 31, 2025
PharmaShots’ Key Highlights of First Quarter 2025
April 1, 2025
Reuters Pharma USA 2025: Pre Conference Talks featuring T.J. Sharpe
March 13, 2025
Ono Enters into an Option Agreement with Reborna Biosciences for RNA-Targeting Small Molecule to treat CNS Disorders
April 1, 2025
Reuters Pharma USA 2025: Post-Conference Talks featuring Rahul Mittal
March 31, 2025
PharmaShots Weekly Snapshots (March 24, 2025 – March 28, 2025)
March 28, 2025
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
×
Email
First Name
Last Name
Company Name
Area/Designation
Daily Newsletter
Weekly Newsletter
Stay Connected
LinkedIn
Twitter
Facebook
instagram
Youtube
Join the PharmaShots family of 12000+ subscribers
Newsletter
Subscribe Now
I accept the
Terms and Conditions
X
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
Subscribe
Modal title
×
Modal body text goes here.
